EU project on intelligent materials to regenerate bone tissue

More than half a million Europeans suffer from disorders in or serious defects of some part of their bone structure. So, graft or implant operations needed to repair the damage depend decisively on the materials used. The Nanobiocom project, funded under the EU's Sixth Framework Programme (FP6), is working on the regeneration and repair of bone tissue. Its aim is to come up with a substitute for bone tissue that can repair the bone and regenerate it in such a way that it will be able to carry out similar functions to those in its natural state.

In the case of significant deterioration of the bone, it may be necessary for the implant to provide both functional and physiological properties of the damaged item. In such circumstances, the bone implants have to comply with certain requisites capable of contributing to a reconstruction of the deteriorated bone tissue in the most efficient and least harmful way possible, without any serious repercussions. Another requirement involves the carrying out of the mechanical functions of the damaged bone while the desired regeneration takes place.

In addition, the solutions have to be capable of remedying particularly serious damage, such as those due to congenital deficiencies, degenerative illnesses, cancerous disorders and other damage caused by accidents. The implants required for this type of solutions are more complex and sophisticated than the small implants known until now.

So the Nanobiocom project will seek to develop a support (scaffold) made out of a compound material that is 'intelligent', proactive, and capable of repairing and regenerating bone tissue. For this purpose, it has to be bioactive, capable of acting on the tissue-generating system and its corresponding genes, as well as responding correctly to the physiological and biological changes, both internal and external, of that system.

It is also necessary for its size and shape characteristics, as well as its mechanical functions, to correspond with those of healthy bones.

The specific tasks of the three-year project are now on fine tuning the intelligent material, based on nanoparticles and of a biodegradable nature. Also in the pipeline is the development of the cell culture in three dimensions, as well as ensuring the biocompatibility of the material.

Ultimately, the scientists involved in the frontier research project hope it will open new doors in the development of nanobiotechnology.

For more information, please visit:
http://nanobiocom.org

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...